Drug Approval | November 21, 2025
AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
The move is expected to be crucial during health crises
The initiative aims to connect startups and tech companies with its business units,
The cleared system pairs a flexible nitinol implant with a deployable prong-locking mechanism, delivering rotational and length stability
_256_384.png)
India presents one of the world’s largest untapped opportunities for neurovascular screening
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
